Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum

• DOI: 10.1007/s11427-007-0053-x
• Publication Date: 2007-07-03T21:21:13Z
• Authors: SongWei Dai; XiaoMin Wang; LiYun Liu; JiFu Liu; ShanShan Wu; LingYun Huang; XueYuan Xiao; DaCheng He
• Keywords: Serum Amyloid A Protein; Lung Neoplasms; Enzyme-Linked Immunosorbent Assay; Sensitivity and Specificity; 3. Good health; Molecular Weight; 03 medical and health sciences; 0302 clinical medicine; Reference Values; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Biomarkers, Tumor; Humans; Neoplasm Staging

Two hundred and eighteen serum samples from 175 lung cancer patients and 43 healthy individuals were analyzed by using Surface Enhaced Laser Desorption/Ionization Time of Flight Mass Spectrome-try (SELDI-TOF-MS). The data analyzed by both Biomarker Wizardtrade mark and Biomarker Patternstrade mark software showed that a protein peak with the molecular weight of 11.6 kDa significantly increased in lung cancer. Meanwhile, the level of this biomarker was progressively increased with the clinical stages of lung cancer. The candidate biomarker was then obtained from tricine one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis by matching the molecular weight with peaks on WCX2 chips and was identified as Serum Amyloid A protein (SAA) by MALDI/MS-MS and database searching. It was further validated in the same serum samples by immunoprecipitation with commercial SAA antibody. To confirm the SAA differential expression in lung cancer patients, the same set of serum samples was measured by ELISA assay. The result showed that at the cutoff point 0.446 (OD value) on the Receiver Operating Characteristic (ROC) curve, SAA could better discriminate lung cancer from healthy individuals with sensitivity of 84.1% and specificity of 80%. These findings demonstrated that SAA could be characterized as a biomarker related to pathological stages of lung cancer.